Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia

NCT01857024 · clinicaltrials.gov ↗

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperphosphataemia
Chronic Kidney Disease

Interventions

DRUG: sevelamer carbonate (Renvela®)

Sponsor

Genzyme, a Sanofi Company